Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OCUPHIRE PHARMA, INC.

(OCUP)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
5.12(c) 5.22(c) 5.27(c) 5.36(c) 5.3101 Last
545 267 403 765 184 156 172 426 39 686 Volume
-1.35% +1.95% +0.96% +1.71% -0.93% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 0,05 M - -
Net income 2021 -56,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,36x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -18,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,77x
Yield 2022 -
Capitalization 90,6 M 90,6 M -
Capi. / Sales 2021 1 811x
Capi. / Sales 2022 -
Nbr of Employees 5
Free-Float 86,3%
More Financials
Company
Ocuphire Pharma, Inc., formerly Rexahn Pharmaceuticals, Inc. is a clinical-stage ophthalmic biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of eye disorders. Its pipeline includes two small-molecule product candidates targeting front and back of the eye indications. Its lead product candidate, Nyxol Eye Drops, is a once-daily preservative-free eye drop... 
Sector
Pharmaceuticals
Calendar
09/28 | 10:00amPresentation
More about the company
All news about OCUPHIRE PHARMA, INC.
09/03OCUPHIRE PHARMA : Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
09/02OCUPHIRE PHARMA : Presenting at Four Conferences in September
AQ
08/12OCUPHIRE PHARMA : Management's Discussion and Analysis of Financial Condition and Results ..
AQ
08/12OCUPHIRE PHARMA : Nyxol plus Low-Dose Pilocarpine Phase 2 Trial Results Show Potential for..
PU
08/12OCUPHIRE PHARMA, INC. : Results of Operations and Financial Condition, Regulation FD Discl..
AQ
08/12OCUPHIRE PHARMA : Earnings Flash (OCUP) OCUPHIRE PHARMA Reports Q2 Revenue $100,000
MT
08/12OCUPHIRE PHARMA : Announces Financial Results for the Second Quarter 2021 and Provides Cor..
AQ
08/12Ocuphire Pharma, Inc. Announces Unaudited Consolidated Earnings Results for the Second ..
CI
08/09OCUPHIRE PHARMA : Presenting at Two Conferences in August
AQ
08/06OCUPHIRE PHARMA : Presenting at Two Conferences in August
AQ
07/22OCUPHIRE PHARMA : Announces Publication in the Journal of Cellular Signaling Featuring its..
AQ
07/22Ocuphire Pharma, Inc. Announces Publication in the Journal of Cellular Signaling Featur..
CI
07/13OCUPHIRE PHARMA : Selected to Present at Multiple Ophthalmic Conferences in July
AQ
07/09OCUPHIRE PHARMA : Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
06/30OCUPHIRE PHARMA, INC. : Regulation FD Disclosure, Other Events, Financial Statements and E..
AQ
More news
News in other languages on OCUPHIRE PHARMA, INC.

- No features available -

More news
Analyst Recommendations on OCUPHIRE PHARMA, INC.
More recommendations
Chart OCUPHIRE PHARMA, INC.
Duration : Period :
Ocuphire Pharma, Inc. Technical Analysis Chart | OCUP | US67577R1023 | MarketScreener
Technical analysis trends OCUPHIRE PHARMA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 5,36 $
Average target price 25,33 $
Spread / Average Target 373%
EPS Revisions
Managers and Directors
Mina Patel Sooch President, Chief Executive Officer & Director
Amy Rabourn Chief Accounting Officer & Vice President-Finance
Cam S. Gallagher Chairman
Mitchell Brigell Head-Clinical Development & Strategy
Bernhard Hoffmann Vice President-Corporate Development & Operations
Sector and Competitors
1st jan.Capi. (M$)
OCUPHIRE PHARMA, INC.-17.41%91
JOHNSON & JOHNSON4.75%433 991
ROCHE HOLDING AG10.87%324 441
PFIZER, INC.19.40%247 760
NOVO NORDISK A/S51.58%233 750
ELI LILLY AND COMPANY37.51%210 490